Exosome Diagnostics Announces Data Demonstrating ExoIntelliScore Prostate Accurately Predicted Gleason Score, Pathologic Stage And Tumor Volume In Patients With Prostate Cancer
VIENNA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, presented new positive data from a clinical study for the company’s novel, urine-based prostate cancer liquid biopsy, ExoIntelliScore™ Prostate (formally referred to as Exo106). The data demonstrated that ExoIntelliScore Prostate accurately predicted in pre-radical prostatectomy (RP) urine samples of patients with prostate cancer, objective clinical features present in RP specimens and also provided initial improved discrimination of RP Gleason Score 4+3, a subset of patients at elevated risk for aggressive disease.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.